At the 2026 NCCN Annual Meeting, CURE sat down with Dr. Thomas Flaig to discuss the rapidly evolving landscape of bladder cancer care. During the interview, he reflected on the dramatic progress made ...
Renal & Urology News: 5-Year RFS May Define “Cure” for Patients With Early Bladder Cancer
Patients with early bladder cancer who have gone 5 years without relapse may be considered “cured,” researchers suggested. In considering outcomes for evaluating how “cure” is defined in early bladder ...
At the 2026 NCCN Annual Meeting, Dr. Charles Peyton spoke with CURE about how a growing number of treatment options is influencing decision-making in bladder cancer care, particul ...
Medical News Today: Urine biomarker may predict bladder cancer treatment response, study finds
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which could help guide bladder cancer therapy decisions.
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.
MarketWatch: ImmunityBio Announces ANKTIVA(R) Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
ImmunityBio Announces ANKTIVA(R) Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
Medical Xpress: Immunotherapy shows early promise in sparing cancer patients from bladder removal
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after ...